Rinsch, C. Andreux, P., Sutton J., Seward E., Knight J., Linney I.,
Sennhenn P.
Urolithin derivatives and methods of use thereof
WO2022162471
Hasleton M., Sennhenn P.
Plasmalogen derivatives and uses thereof
WO2022263927
Menzer W., Knobloch G., Lieleg C., Schomburg A., Ladurner A.,
Sennhenn P.
ALC1 inhibitors and synergy with PARPi
WO2022117782
Sennhenn P., Bissinger S., Loferer H., Bancroft D., Michels T.,
Khandelwal N.
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
IL297481A•2022-12-01
Eikan Mishima, Toshitaka Nakamura, Jiashuo Zheng, Weijia Zhang, André Santos Dias Mourão, Sennhenn P., Marcus Conrad
DHODH inhibitors sensitize cancer cells to ferroptosis via FSP1 inhibition
Matters Arising, available at Research Square https://doi.org/10.21203/rs.3.rs-2190326/v1
Akito Koike, Frank Becker, Sennhenn P., Jason Kim, Jenny Zhang, Stefan Hannus, Klaus Brehm
Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy
PLoS Negl Trop Dis 2022, 16(10)
Akito Koike, Katia Cailliau, Jerome Vicogne, Frank Becker, Sennhenn P., Colette Dissous, Stefan Hannus, Klaus Brehm
In vitro screening of kinase inhibitors on Echinococcus multilocularis
29th annual meeting of German Society for Parasitology, Bonn, March 15-17, 2021
Tillmann Michels, Antonio Sorrentino, Ayse Nur Menevse, Stefan Bissinger, Sennhenn P., Valentina Volpin, Sabrina Genssler Hannes Loferer, Christian Kohler, Rainer Spang, Michael Rheli, Christian Schmidl, Macro Breinig, Michael Boutros, Sebastian Meier-Ewert, Apollon Papadimitriou, Philipp Beckhove and Nisit Khandelwal
Salt-inducible kinase 3 facilitates tumor cell resistance against cytotoxic T cell attack by shifting TNF signaling from apoptosis to survival
AACR Virtual Annual Meeting, 2020
Sennhenn P., Meier-Ewert S., Khandelwal N.
Dasatinib and other protein kinase inhibitors and methods of preparation and uses thereof for treating proliferative disorders such as cancer
WO2020083909
Sennhenn P., Meier-Ewert S., Khandelwal N., Bancroft D.
Heterocyclic kinase inhibitors and uses thereof for treatment of proliferative disorders
WO2020083926
Sorrentino A., Beckhove, P., Michels T., Khandelwal N., Boutros M., Breinig M., Sennhenn P., Meier-Ewert S.
Intracellular kinase associated with resistance against anti-tumor immune responses, and uses thereof
WO2018193084
Trebosc V., Gartenmann S., Royet K., Manfredi P., Tötzl M., Schellhorn B., Pieren M., Tigges M., Lociuro S., Sennhenn P., Gitzinger M., Bumann D., Kemmer C.
A novel genome editing platform for drug resistant Acinetobacter baumannii revealed an AdeR-unrelated tigecycline resistance mechanism.
Antimicrobial Agents and Chemotherapy, 2016, 60, 7263-7271
Schellhorn B., Kemmer C., Lucchini V., Gartenmann S., Trebosc V., Deroose F., Sennhenn P. Lociuro S., Tigges M., Gitzinger M., Pieren M.
Identification of VanR inhibitors re-sensitising vancomycin-resistant enterococci (VRE) towards glycopeptide antibiotics.
26th ECCMID Congress, Amsterdam, Netherlands April 9 - 12, 2016
Conrad M., Schick J., Proneth B., Sennhenn P.
Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
WO2016075137 PCT Int. Appl. 2016.
Conrad M., Schick J., Proneth B., Sennhenn P.
Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
WO2015007730 PCT Int. Appl. 2015.
Conrad M., Schick J., Proneth B., Sennhenn P.
Tissue protection by non-apoptotic cell death inhibitors.
BioVaria, München, Germany, May 11, 2015.
Chellat M., Raguz L., Sephton M., Züger P., Brand M., Schneider P., Tigges M., Gitzinger M., Sennhenn P., Pieren M., Levi A., Schellhorn B., Gygaxc D., Spiesc P., Riedl R.
Tackling Antibiotic Resistance by Transcription Repressor Inhibitory Compounds
Molecules for the Life Sciences, Swiss Chemical Society ILMAC-FH-Award 2013.
Backes A., Sennhenn P., Müller G.
Design principles of kinase inhibitors.
Protein Kinase Targets; Eds. Mueller G., Klebl B.; VCH-Wiley: Weinheim, Germany, 2011
Müller G., Sennhenn P. Woodcock T., Neumann L.
The retro-design concept for novel kinase inhibitors.
IDrugs. 2010, 13, 457 - 466.
Sennhenn P., Hafenbradl D., Brandstetter T., Woodstock T., Koestler R., Schoop A., Vogt J., Walch h., Backes A., Baumann M., Zybarth G., Mueller G.
Novel 5-sulphonylamino-benzothiophenes as anti-cancer agents.
EP10157556
Henry C., Sennhenn P., Woodstock T., Schoop A.
Novel 5-acylamino-benzothiophenes as anti-cancer agents.
EP10157558
Brandstetter T., Eickhoff J., Koestler R., Schoop A., Sennhenn P., Becker F., Kauffmann C.
Dihydropteridinones as PLK Inhibitors.
WO2009130016 PCT Int. Appl. 2009.
Reiser U., Kraemer O., Sennhenn P., Spevak W.
Spiro- (THO) benzopyran-2, 4’-piperidine- and cyclohexane derivatives as inhibitors of specific cell cycle enzymes.
WO2007128782 PCT Int. Appl. 2007.
Reiser U., Ettmayer P., Kraemer O., Sennhenn P., Spevak W.
New chemical compounds
WO2007144370 PCT Int. Appl. 2007.
Sennhenn P., Mantoulidis A., Treu M., Tontsch-Grunt U., Spevak W., McConnel D., Schoop A., Brueckner R., Jacobi A., Guertler U., Schnapp G., Klein C. Himmelsbach F., Pautsch A., Betzemeier B., Herfurth L., Mack J., Wiedenmayer D., Bader G., Reiser U.
Alpha-Carbolines as CDK-1 Inhibitors.
WO2006131552 PCT Int. Appl. 2006.
Rudolph J., Sennhenn P., Vlaar C., Sharpless K. B.
Smaller substituents on nitrogen facilitate the osmium-catalyzed asymmetric aminohydroxylation.
Angew. Chem., Intern. Ed. 1996, 35, 2810-2813.
Helmchen G., Kudis S., Sennhenn P., Steinhagen H.
Enantioselective catalysis with complexes of asymmetric P,N-chelate ligands.
Pure Appl. Chem. 1997, 69, 513-518.
Peer M., de Jong J., Kiefer M., Langer T., Rieck H., Schell H., Sennhenn P., Sprinz J., Steinhagen, H.
Preparation of chiral phosphorus, sulfur and selenium containing 2-aryloxazolines.
Tetrahedron 1996, 52, 7547-7583.
Knuehl G., Sennhenn P., Helmchen, G.
New chiral ß-phosphinocarboxylic acids and their application in palladium-catalyzed asymmetric allylic alkylations.
J. Chem. Soc. Chem. Commun. 1995, 1845-1846.
Sennhenn P., Gabler B., Helmchen G.
Enantiomerically pure cycloalkenylacetic acid derivatives via Pd-catalyzed asymmetric allylic alkylation and subsequent enantiomeric enrichment via iodolactones.
Tetrahedron Letters 1994, 35, 8595-8598.
A full list of publications is available on request.
|
 |
Sennhenn P.
Ferroptosis, a Novel Druggable Cell Death Pathway: From Primary Screening Hit to Clinical Candidate
SAGIM Meeting, San Diego, CA, USA, April 12, 2019
Sennhenn P.
Long-Residence Time Kinase Inhibitors: Deep Pocket Binders by Fragment-Based Design
Fragment-Based Drug Design, Tokyo, Japan, Feb. 07, 2011
Sennhenn P.
Medicinal Chemistry: A Rule-Based Science?
9th Swiss Course on Medicinal Chemistry, Leysin, Switzerland, Oct. 12, 2010.
Sennhenn P.
Long Residence Time Kinase Inhibitors: Binding Kinetics in Fragment-Based Drug Design.
Chemistry fro Preventing & Combating Disease, ACS National Meeting, Boston, MA, USA, Aug. 23, 2010.
Sennhenn P.
Post RO5 Optimization Parameters: Design Principles of Protein Kinase Inhibitors
Training Course at Screening, MedChem and ADMET Europe, Berlin, Germany, Feb. 26, 2009.
Sennhenn P.
Kinase Inhibitors with Tailored Binding Kinetics by Fragment-Based Design
Screening, MedChem and ADMET Europe, Berlin, Germany, Feb. 25, 2009.
Sennhenn P.
Fragment-Based Lead Discovery: a Viable Alternative to HTS?
Ringberg Meeting 2009: Academia Meets Industry, Ringberg, Germany, Jan. 08, 2009.
Sennhenn P.
Fragment-Based Lead Generation for Novel Kinase Inhibitors.
Small Molecules, Antibodies and Natural Products: Multiple Faces of Medicinal Chemistry, Leuven, Belgium, Nov. 07, 2008.
Sennhenn P.
Design Principles of Protein Kinase Inhibitors
Pre-Workshop at CHI 6th Annual Discovery on Target, Boston, MA, USA, Oct. 20., 2008.
Sennhenn P.
The Choice of the Aurora Enzyme is an Imprortant Determinant in the Ligand Finding Process.
Cell Baded Assays, München, Germany, May 21, 2008.
Sennhenn P.
The privileged structure concept applied to protein kinase Inhibitors.
GTCbio’s 3rd Annual Conference on Protein Kinases in Drug Discovery, San Diego, CA, USA, May 05, 2008.
Sennhenn P.
Selectivity of kinase inhibitors: From PknG to Aurora.
GTCbio’s 2nd Annual Conference on Protein Kinases in Drug Discovery, Boston, MA, USA, May 31, 2007.
Sennhenn P.
Aurora kinase inhibitors: Lead structure identification from the tetrahydrobenzo[b]thiophene class.
Minisymposium: Drug Discovery and Design, AACR Annual Meeting,
Los Angeles, CA, USA, April 17, 2007.
|
